The RAGE pathway in inflammatory myopathies and limb girdle muscular dystrophy

Acta Neuropathol. 2005 Sep;110(3):247-54. doi: 10.1007/s00401-005-1043-3. Epub 2005 Jun 29.

Abstract

Oxidative stress and nuclear factor-kappaB (NF-kappaB) activation are linked to the pathogenesis of many metabolic, degenerative, and chronic inflammatory diseases. Activation of the receptor for advanced glycation end products (RAGE) by its specific ligand N(epsilon)-carboxymethyllysine (CML) results in the activation of NF-kappaB and the production of proinflammatory cytokines. To determine whether engagement of RAGE contributes to the pathogenesis of inflammatory myopathies, we performed immunohistochemical studies on the presence of CML-modified proteins, RAGE and activated NF-kappaB in muscle biopsies of patients with polymyositis (PM, n=10), dermatomyositis (DM, n=10), limb girdle muscular dystrophy (LGMD, n=10) and in 10 controls with normal muscle biopsy results. In inflammatory myopathies CML, RAGE and NF-kappaB were detected in mononuclear cells and in regenerating muscle fibers. CML, NF-kappaB and, to a lesser extent, RAGE were also found in degenerating muscle fibers, but colocalization of CML, RAGE and NF-kappaB was only seen in infiltrating mononuclear cells and regenerating muscle fibers. Immunofluorescence double labeling demonstrated an expression of CML, RAGE and NF-kappaB in CD4-, CD8-, CD22- and CD68-positive mononuclear cells. Western blot analysis showed an increased immunoreactivity for CML-modified proteins in PM and DM. In LGMD, CML, RAGE and NF-kappaB were found in regenerating muscle fibers and less frequently in degenerating muscle fibers, and with lower staining intensities than in inflammatory myopathies. Our data suggests that the CML-RAGE-NF-kappaB pathway is an evident proinflammatory pathomechanism in mononuclear effector cells in PM and DM. RAGE-mediated NF-kappaB activation may be involved in muscle fiber regeneration in inflammatory myopathies and LGMD.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Dermatomyositis / immunology
  • Dermatomyositis / metabolism
  • Dermatomyositis / physiopathology
  • Glycation End Products, Advanced
  • Humans
  • Immunohistochemistry
  • Leukocytes, Mononuclear / immunology
  • Leukocytes, Mononuclear / metabolism
  • Lysine / analogs & derivatives
  • Lysine / metabolism
  • Middle Aged
  • Muscle Fibers, Skeletal / metabolism
  • Muscle Fibers, Skeletal / pathology
  • Muscle, Skeletal / immunology
  • Muscle, Skeletal / metabolism*
  • Muscle, Skeletal / physiopathology
  • Muscular Dystrophies, Limb-Girdle / immunology
  • Muscular Dystrophies, Limb-Girdle / metabolism*
  • Muscular Dystrophies, Limb-Girdle / physiopathology
  • Myositis / immunology
  • Myositis / metabolism*
  • Myositis / physiopathology
  • NF-kappa B / metabolism
  • Polymyositis / immunology
  • Polymyositis / metabolism
  • Polymyositis / physiopathology
  • Receptor for Advanced Glycation End Products
  • Receptors, Immunologic / immunology
  • Receptors, Immunologic / metabolism*
  • Regeneration / physiology
  • Signal Transduction*
  • Transcriptional Activation / physiology

Substances

  • Glycation End Products, Advanced
  • NF-kappa B
  • Receptor for Advanced Glycation End Products
  • Receptors, Immunologic
  • N(6)-carboxymethyllysine
  • Lysine